ASBrS Recommends IceCure’s Cryoablation for Low-Risk Breast Cancer Treatment

Key Facts

The American Society of Breast Surgeons (ASBrS) has updated its 2026 Resource Guide to include cryoablation as a recommended treatment option for early-stage, low-risk breast cancer patients. This pivotal recommendation is supported by robust clinical data from IceCure Medical’s ICE3 study and a favorable benefit-risk assessment by an FDA Advisory Panel. The inclusion in these clinical guidelines is expected to significantly accelerate the commercial adoption of IceCure’s ProSense technology following official FDA clearance. Industry analysts suggest that this milestone will facilitate insurance reimbursement and drive broader adoption among surgical professionals globally. For IceCure Medical (Nasdaq: ICCM), this development represents a major catalyst for long-term revenue growth and market penetration in the oncology sector. The move underscores a shift toward minimally invasive solutions in breast cancer management.